Artax Biopharma develops oral small-molecule Nck modulators that dampen inappropriate T-cell activation at the TCR signaling level without globally suppressing the immune system. It targets autoimmune diseases including psoriasis, atopic dermatitis, and rheumatoid arthritis. Lead asset AX-158 is a first-in-class Phase 2 program modulating Signal 1 instead of downstream cytokines.
acquisitions n=0
No cited completed company acquisition recorded.
traction n=0
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
valuations n=0
No cited valuation with an explicit basis is recorded.
revenue multiples n=0
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.